Navigation Links
Abbott Receives CE Mark Certification

The CE Mark certification has been received by the global healthcare company Abbott towards a new test for detecting the Neissera gonorrhoeae (NG) and Chlamydia trachomatis // (CT) sexually transmitted pathogens. This will enable the company to sell the product in the European Union (EU). The test will be conducted through the Abbott m2000?, which uses real time polymerase chain reaction (PCR) and magnetic particle technology.

Where sexually transmitted diseases are concerned, gonorrhea and chlamydia are the most common, and accurate detection of these diseases can serve to avoid serious illness at a later stage. The European laboratories will be able to get highly reliable test results through the combination of the Abbott m2000 system and the Abbott RealTime? CT/NG assay. The amplified nucleic acid tests can be done on urine samples in a non-invasive manner. Processes like molecular tests, sample preparation and data analysis are automated through the use of the m2000.

As many as 300 million sexually transmitted diseases infections occur across the world annually, according to the World Health Organization (WHO), of which gonorrhea accounts for 55 million and chlamydia accounts for another 85 million. No symptoms are seen in the case of these diseases in 10% of the men and 80% of the women who are infected, even though they are fully capable of infecting others with the disease.

If they are not properly treated, it can result in serious complications like urethritis, sterility, and pelvic inflammatory diseases. Antibiotics are capable of curing both the strains of the disease. Abbott has an alliance with the Celera Diagnostics in Europe through which the test will be made available. Tests are being conducted to detect the hepatitis B virus and HIV/AIDS also through the Abbott m2000 system.
'"/>




Page: 1

Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott to Subsidize Price of HIV Drug
5. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
6. Fifth US Patient Receives Artificial Heart
7. Northfield Labs Receives FDA Comments
8. British MPs Say Prostate Cancer Receives Low Priority in the NHS
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Abbott Receives Mark Certification

(Date:8/29/2008)... WASHINGTON, Aug. 29 /PRNewswire-USNewswire/ -- Th...onsistent procedures to allow the public to,see ex...ished today in the,Federal Register http://edocke...will ensure that the best and latest available evi... risk assessments for health,standards regulating ...
(Date:8/29/2008)...iation may have caused chromosomal change that rai... FRIDAY, Aug. 29 (HealthDay News) -- Some Japanese...in Hiroshima and Nagasaki experienced key genetic ...of thyroid cancer, new research indicates. , Pa...o a particular genetic mutation involving the so-c...
(Date:8/29/2008)... LEEDS, England, August 29 /PRNewswire/ --, - MYA...ce for Recent,Big Brother Stars but the big Questi...as, mirrors all around and being on national,telev...ct on how you feel,about the way you look. For man... a reality. Upon leaving the house contestants may...
(Date:8/29/2008)... Dr. Milton Owens and the Co... Southern California to provide protection for cas...on, and the Hispanic community is benefiting. , ...ust 29, 2008 -- Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin...
Breaking Medicine News(10 mins):Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2
...ccording to a recent study, are increasingly turni...ease. In this context physicians need to be aware...de the patients to the most reliable, accurate and...niversity of Pennsylvania Cancer Center in Philade...
...ems to be the latest mantra of Pfizer. The pharma...ree antifungal drug to 50 countries hardest hit by...close on the heels of the South African Government...ompanies. In an announcement on Wednesday Pfizer ...
...ich are protective substances, produced by the bod...em kill the TB bacteria, researchers in the UK rep...he journal Nature Medicine, these heat-shock prote...ody help cells survive stressful times and bolster...
...rket in India is expected to grow into a three bil...ndia finance report. The big leap is expected to ...one billion dollars. Biogenerics, biopharmaceutic...tors are all poised for the big leap, both nationa...
Other Medicine News:
(Date:8/26/2008)...stCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today anno...om the CUSTOM II trial was published in the most r...rvention. The lead author of the article was,Dr. P...r Utrecht, Utrecht,The Netherlands on behalf of t...across Europe., The one-year CUSTOM II trial, a s...
(Date:8/25/2008).../ -- Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assigne...,the benefit of creditors, announced today that al...d at a sealed bid auction on October 10,2008., S...opa-Carbidopa that,is the current gold standard tr... estimated at approximately $250 million. Signific...
(Date:8/22/2008)..., - Dangerous Bacteria Infect Three Million Peopl...tried can also be innovative: already in,Ancient G...ial. This,ability is now playing an important role... In a worldwide noted field test, a whole hospital...rg, Germany, was equipped with,door handles, door ...
(Date:8/21/2008)...tial in independent study of ad...g. 21 /- A recently published article...ation has expanded our,understanding of the clinic...in adult patients at risk for organ rejection or i...ablo Sanchez-Velasco and his colleagues in the Can...
Breaking Medicine Technology:XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 2New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 3Commonwealth Fund Commission issues reform recommendations for next president 6383 1Commonwealth Fund Commission issues reform recommendations for next president 6383 2Commonwealth Fund Commission issues reform recommendations for next president 6383 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 1FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 2FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 4BIO key Reports Third Quarter 2007 Results 1228 1BIO key Reports Third Quarter 2007 Results 1228 2BIO key Reports Third Quarter 2007 Results 1228 3BIO key Reports Third Quarter 2007 Results 1228 4BIO key Reports Third Quarter 2007 Results 1228 5Predicting the future in ovarian cancer 6379 1Predicting the future in ovarian cancer 6379 2
...USINESS WIRE)--Jun 7, 2007 - Clinical results from...the American,Headache Society (AHS) annual meeting...itonin gene-related peptide (CGRP),receptor antago...two hours after dosing compared to placebo, and th...as generally well tolerated in,the study. Response...
... 900-mcg dosed every two weeks achieved an SVR rat...(ITT analysis), with,more favorable quality-of-lif...ire-FirstCall/ -- Human,Genome Sciences, Inc. toda...2b clinical trial of Albuferon(R) (albinterferon a...-naive patients with,genotype 1 chronic hepatitis ...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
Medicine Products: